This item is non-discoverable
Ulu, Gizem Tuğçe
Loading...
Profile URL
Name Variants
Ulu, Gizem Tugce
Job Title
Email Address
Main Affiliation
01.01. Units Affiliated to the Rectorate
Status
External
Website
ORCID ID
Scopus Author ID
Turkish CoHE Profile ID
Google Scholar ID
WoS Researcher ID
Sustainable Development Goals
1NO POVERTY
0
Research Products
2ZERO HUNGER
0
Research Products
3GOOD HEALTH AND WELL-BEING
9
Research Products
4QUALITY EDUCATION
0
Research Products
5GENDER EQUALITY
1
Research Products
6CLEAN WATER AND SANITATION
0
Research Products
7AFFORDABLE AND CLEAN ENERGY
0
Research Products
8DECENT WORK AND ECONOMIC GROWTH
0
Research Products
9INDUSTRY, INNOVATION AND INFRASTRUCTURE
1
Research Products
10REDUCED INEQUALITIES
0
Research Products
11SUSTAINABLE CITIES AND COMMUNITIES
0
Research Products
12RESPONSIBLE CONSUMPTION AND PRODUCTION
0
Research Products
13CLIMATE ACTION
0
Research Products
14LIFE BELOW WATER
0
Research Products
15LIFE ON LAND
0
Research Products
16PEACE, JUSTICE AND STRONG INSTITUTIONS
1
Research Products
17PARTNERSHIPS FOR THE GOALS
0
Research Products
Documents
9
Citations
122
h-index
4
This researcher does not have a WoS ID.
Publication Collaboration
| Affiliation Name | Count |
|---|---|
| Izmir Institute of Technology | 9 |
| University of Stuttgart | 5 |
| Ben-Gurion University of the Negev | 5 |
| Abdullah Gül University | 4 |
| Agricultural University of Tirana | 1 |
1 / 5
Data obtained from OpenAlex
Scholarly Output
10
Articles
4
Views / Downloads
60176/4121
Supervised MSc Theses
1
Supervised PhD Theses
0
WoS Citation Count
22
Scopus Citation Count
124
Patents
0
Projects
0
WoS Citations per Publication
2.20
Scopus Citations per Publication
12.40
Open Access Source
6
Supervised Theses
1
| Journal | Count |
|---|---|
| Macromolecular Bioscience | 2 |
| Annals Of Oncology | 1 |
| Biodiversity and Biomedicine: Our Future | 1 |
| Methods in Molecular Biology | 1 |
| Pharmaceutics | 1 |
Current Page: 1 / 2
Scopus Quartile Distribution
Competency Cloud
10 results
Scholarly Output Search Results
Now showing 1 - 10 of 10
Conference Object Determination of Therapeutic Effects of Multifunctional Micelle-Based Nanocarriers on Breast Cancer Cells(Elsevier, 2021) Ulu, Gizem Tuğçe; Baran, Yusuf; Bayram, Nazende Nur; Ulu, Gizem Tuğçe; Abdulhadi, N.; Gurdap, S.; Isoglu, A.; Isoglu, S. D.; Baran, Yusuf; 01.01. Units Affiliated to the Rectorate; 04.03. Department of Molecular Biology and Genetics; 01. Izmir Institute of Technology; 04. Faculty of ScienceBackground: Breast cancer is the most common and frequent cause of death in women in all types of cancer. Current treatment protocols do not provide a complete cure and targeting therapy can provide an important avenue for successful treatment of breast cancer. In this study, we aim to determine the therapeutic effects of the drug-conjugated carrier system with the conjugation of peptide sequence and antibody on HER2-positive breast cancer cells.Master Thesis Determination of Therapeutic Effects of Multifunctional Micelle-Based Nanocarriers on Breast Cancer Cells(Izmir Institute of Technology, 2019) Ulu, Gizem Tuğçe; Baran, Yusuf; Ulu, Gizem Tuğçe; Baran, Yusuf; 01.01. Units Affiliated to the Rectorate; 04.03. Department of Molecular Biology and Genetics; 01. Izmir Institute of Technology; 04. Faculty of ScienceBreast cancer is the most common and frequent cause of death among women composed to all types of cancer. Current treatment protocols do not provide complete cure or selective drug delivery while targeted therapy can provide an important avenue for successful treatment of breast cancer. In this study, therapeutic effects of drug-conjugated nanocarrier system with enhanced stability and double moiety pH-sensitivity on breast cancer (SKBR-3- HER-2- positive), normal breast epithelial (MCF-10A, HER-2-negative) and chronic myeloid leukemia (K562, HER-2-negative) cells were determined. With this approach, SKBR-3 cells were targeted by single nanocarriers having selectivity with unused peptide ligand (HER-2), stability with cross-linking of core moiety, and cleavage by two sites of pHeffect and drug release properties. After physicochemical characterization of micellebased nanocarriers, cytotoxic, apoptotic and cytostatic effects of doxorubicin conjugated micelles were determined. Doxorubicin conjugated micelles with HER-2 peptide (DOX-HER-2-NCs) had more cytotoxic effects on HER-2 positive cells. Additionally, intracellular amounts of doxorubicin is higher in SKBR-3 cells with applied DOX-HER-2-NCs as determined by fluorescence imaging. The apoptosis rate was increased on SKBR-3 at 50% cell growth inhibition (IC50) as determined by Annexin-V/Propidium iodide double staining. However, there was not any significant change in loss of mitochondrial membrane potential. Additionally, DOX-HER-2-NCs resulted in cell cycle arrest at G2/M-phase in response to IC50 value. Besides, protein level of Bcl-2 did not change while protein level of Bax and Caspase-3 were increased as determined by Western Blotting. This project provides novel and more effective treatment of breast cancer by using multifunctional properties of nanocarriers.Conference Object Advantage of Co-Culture Strategy for Targeted Cancer Treatment and in Vitro Studies(Elsevier, 2021) Ulu, Gizem Tuğçe; Ulu, Gizem Tuğçe; Bayram, Nazende Nur; Baran, Yusuf; Dinçer İşoğlu, Sevil; Baran, Yusuf; 01.01. Units Affiliated to the Rectorate; 04.03. Department of Molecular Biology and Genetics; 01. Izmir Institute of Technology; 04. Faculty of ScienceBreast cancer tissues include carcinoma cells and stromal cells, and intra-tumoral stroma that consists of different types of cells. For this point, cell-cell interaction and communication have a potential role in cancer progression. Mono-cell culture is used for cancer treatment approaches. However, cell-cell interaction and communication can not be evaluated on mono-culture cells. So, co-culture models provide low-cost screening to determine cell proliferation for drug application before moving forward to in vivo models. Also, determination of cell morphology in co culture system is critical to understand advantages.Article Citation - WoS: 3Citation - Scopus: 3Her2-Specific Peptide (ltvspwy) and Antibody (herceptin) Targeted Core Cross-Linked Micelles for Breast Cancer: a Comparative Study(MDPI, 2023) Bayram, N.N.; Baran, Yusuf; Ulu, Gizem Tuğçe; Abdulhadi, N.A.; Gürdap, S.; İşoğlu, İ.A.; Baran, Yusuf; İşoğlu, S.D.; 04.03. Department of Molecular Biology and Genetics; 04. Faculty of Science; 01. Izmir Institute of Technology; 01.01. Units Affiliated to the RectorateThis study aims to prepare a novel breast cancer-targeted micelle-based nanocarrier, which is stable in circulation, allowing intracellular drug release, and to investigate its cytotoxicity, apoptosis, and cytostatic effects, in vitro. The shell part of the micelle is composed of zwitterionic sulfobetaine ((N-3-sulfopropyl-N,N-dimethylamonium)ethyl methacrylate), while the core part is formed by another block, consisting of AEMA (2-aminoethyl methacrylamide), DEGMA (di(ethylene glycol) methyl ether methacrylate), and a vinyl-functionalized, acid-sensitive cross-linker. Following this, a targeting agent (peptide (LTVSPWY) and antibody (Herceptin®)), in varying amounts, were coupled to the micelles, and they were characterized by 1H NMR, FTIR (Fourier-transform infrared spectroscopy), Zetasizer, BCA protein assay, and fluorescence spectrophotometer. The cytotoxic, cytostatic, apoptotic, and genotoxic effects of doxorubicin-loaded micelles were investigated on SKBR-3 (human epidermal growth factor receptor 2 (HER2)-positive) and MCF10-A (HER2-negative). According to the results, peptide-carrying micelles showed a higher targeting efficiency and better cytostatic, apoptotic, and genotoxic activities than antibody-carrying and non-targeted micelles. Also, micelles masked the toxicity of naked DOX on healthy cells. In conclusion, this nanocarrier system has great potential to be used in different drug-targeting strategies, by changing targeting agents and drugs. © 2023 by the authors.Book Part Citation - Scopus: 86The Role of Mirna in Cancer: Pathogenesis, Diagnosis, and Treatment(Humana Press, 2022) Uzuner, Erez; Ulu, Gizem Tuğçe; Ulu, Gizem Tuğçe; Baran, Yusuf; Gürler, Sevim Beyza; Baran, Yusuf; 01.01. Units Affiliated to the Rectorate; 04.03. Department of Molecular Biology and Genetics; 01. Izmir Institute of Technology; 04. Faculty of ScienceCancer is also determined by the alterations of oncogenes and tumor suppressor genes. These gene expressions can be regulated by microRNAs (miRNA). At this point, researchers focus on addressing two main questions: “How are oncogenes and/or tumor suppressor genes regulated by miRNAs?” and “Which other mechanisms in cancer cells are regulated by miRNAs?” In this work we focus on gathering the publications answering these questions. The expression of miRNAs is affected by amplification, deletion or mutation. These processes are controlled by oncogenes and tumor suppressor genes, which regulate different mechanisms of cancer initiation and progression including cell proliferation, cell growth, apoptosis, DNA repair, invasion, angiogenesis, metastasis, drug resistance, metabolic regulation, and immune response regulation in cancer cells. In addition, profiling of miRNA is an important step in developing a new therapeutic approach for cancer. © 2022, Springer Science+Business Media, LLC, part of Springer Nature.Book Part Citation - Scopus: 3Personalized Biomedicine in Cancer: From Traditional Therapy To Sustainable Healthcare(Elsevier, 2020) Ulu, Gizem Tuğçe; Baran, Yusuf; Baran,Y.; 01. Izmir Institute of Technology; 01.01. Units Affiliated to the Rectorate; 04.03. Department of Molecular Biology and Genetics; 04. Faculty of ScienceWhat images are coming to your mind when you think about sustainable and qualified life? The main picture drawn is healthcare. Many people suffer from cancer; more than 18.1 million people were diagnosed with cancer and 9.6 million people died from cancer worldwide in 2018. Therefore many diagnosis and treatment strategies that are shaped and regulated by biomedicine approaches have been developed to solve this problem. Biomedicine is an interdisciplinary science to understand the interaction of biological, chemical, and physiological principles. These principles should be brought together to be applicable and sustainable for qualified life. Drug discovery and combination therapy using nanocarriers and natural compounds are being innovated as new approaches and opportunities for cancer treatment. Theoretically and practically, there is no limit to the development of new biomedicinal tools for personalized medicine in cancer. Therefore personalized medicine plays an important role for reaching successful therapy with low cost. By discovering the diverse potential of biomedicine, we can provide better healthcare in the world. © 2020 Elsevier Inc. All rights reserved.Conference Object Peptıde Targeted Core Cross-lınked Mıcelles For Dox Delıvery To Her2 Expressıng Cancer Cells(Mary Ann Liebert, 2022) Bayram, Nazende Nur; Ulu, Gizem Tuğçe; Baran, Yusuf; Ulu, Gizem Tuğçe; Baran, Yusuf; Dinçer İşoğlu, Sevil; 01.01. Units Affiliated to the Rectorate; 04.03. Department of Molecular Biology and Genetics; 01. Izmir Institute of Technology; 04. Faculty of ScienceIn this study, we prepared a novel targeted and extra stable micellar nanocarrier that can facilitate intracellular drug release. First, ((N-3-sulfopropyl-N, N-dimethylammonium)ethyl methacrylate was synthesized by RAFT polymerization, and it was followed by copolymerization of macroCTA with AEM in the presence of an aciddegradable cross-linker. Then, a peptide estimated by phage display for HER-2 recognition was incorporated into these core cross-linked micelles with carbodiimide reaction.Article Citation - WoS: 6Citation - Scopus: 6Therapeutic Potentials of Inhibition of Jumonji C Domain-Containing Demethylases in Acute Myeloid Leukemia(Aves, 2020) Koca, Duygu; Kiraz, Yağmur; Hastar, Nurcan; Baran, Yusuf; Engür, Selin; Ulu, Gizem Tuğçe; Kiraz, Yağmur; Ulu, Gizem Tuğçe; Çekdemir, Demet; Baran, Yusuf; 01.01. Units Affiliated to the Rectorate; 04.03. Department of Molecular Biology and Genetics; 01. Izmir Institute of Technology; 04. Faculty of ScienceAcute myeloid leukemia (AML) is a complex disease affected by both genetic and epigenetic factors. Histone methylation and demethylation are types of epigenetic modification in chromatin remodeling and gene expression. Abnormal expression of histone demethylases is indicated in many types of cancer including AML. Although many commercial drugs are available to treat AML, an absolute cure has not been discovered yet. However, inhibition of demethylases could be a potential cure for AML. Methylstat is a chemical agent that inhibits the Jumonji C domain-containing demethylases.Article Citation - Scopus: 13Her2-Targeted, Degradable Core Cross-Linked Micelles for Specific and Dual Ph-Sensitive Dox Release(John Wiley and Sons Inc, 2022) Bayram, N.N.; Baran, Yusuf; Ulu, Gizem Tuğçe; Topuzoğulları, M.; Baran, Y.; Dinçer, İşoğlu, S.; 04.03. Department of Molecular Biology and Genetics; 04. Faculty of Science; 01. Izmir Institute of Technology; 01.01. Units Affiliated to the RectorateHere, a targeted, dual-pH responsive, and stable micelle nanocarrier is designed, which specifically selects an HER2 receptor on breast cancer cells. Intracellularly degradable and stabilized micelles are prepared by core cross-linking via reversible addition−fragmentation chain-transfer (RAFT) polymerization with an acid-sensitive cross-linker followed by the conjugation of maleimide–doxorubicin to the pyridyl disulfide-modified micelles. Multifunctional nanocarriers are obtained by coupling HER2-specific peptide. Formation of micelles, addition of peptide and doxorubicin (DOX) are confirmed structurally by spectroscopical techniques. Size and morphological characterization are performed by Zetasizer and transmission electron microscope (TEM). For the physicochemical verification of the synergistic acid-triggered degradation induced by acetal and hydrazone bond degradation, Infrared spectroscopy and particle size measurements are used. Drug release studies show that DOX release is accelerated at acidic pH. DOX-conjugated HER2-specific peptide-carrying nanocarriers significantly enhance cytotoxicity toward SKBR-3 cells. More importantly, no selectivity toward MCF-10A cells is observed compared to HER2(+) SKBR-3 cells. Formulations cause apoptosis depending on Bax and Caspase-3 and cell cycle arrest in G2 phase. This study shows a novel system for HER2-targeted therapy of breast cancer with a multifunctional nanocarrier, which has higher stability, dual pH-sensitivity, selectivity, and it can be an efficient way of targeted anticancer drug delivery. © 2021 Wiley-VCH GmbHArticle Citation - WoS: 13Citation - Scopus: 13Her2-Targeted, Degradable Core Cross-Linked Micelles for Specific and Dual Ph-Sensitive Dox Release(John Wiley and Sons Inc., 2021) Bayram, Nazende Nur; Ulu, Gizem Tuğçe; Baran, Yusuf; Ulu, Gizem Tuğçe; Dinçer İşoğlu, Sevil; 01.01. Units Affiliated to the Rectorate; 04.03. Department of Molecular Biology and Genetics; 01. Izmir Institute of Technology; 04. Faculty of ScienceHere, a targeted, dual-pH responsive, and stable micelle nanocarrier is designed, which specifically selects an HER2 receptor on breast cancer cells. Intracellularly degradable and stabilized micelles are prepared by core cross-linking via reversible addition-fragmentation chain-transfer (RAFT) polymerization with an acid-sensitive cross-linker followed by the conjugation of maleimide-doxorubicin to the pyridyl disulfide-modified micelles. Multifunctional nanocarriers are obtained by coupling HER2-specific peptide. Formation of micelles, addition of peptide and doxorubicin (DOX) are confirmed structurally by spectroscopical techniques. Size and morphological characterization are performed by Zetasizer and transmission electron microscope (TEM). For the physicochemical verification of the synergistic acid-triggered degradation induced by acetal and hydrazone bond degradation, Infrared spectroscopy and particle size measurements are used. Drug release studies show that DOX release is accelerated at acidic pH. DOX-conjugated HER2-specific peptide-carrying nanocarriers significantly enhance cytotoxicity toward SKBR-3 cells. More importantly, no selectivity toward MCF-10A cells is observed compared to HER2(+) SKBR-3 cells. Formulations cause apoptosis depending on Bax and Caspase-3 and cell cycle arrest in G2 phase. This study shows a novel system for HER2-targeted therapy of breast cancer with a multifunctional nanocarrier, which has higher stability, dual pH-sensitivity, selectivity, and it can be an efficient way of targeted anticancer drug delivery.